Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Five research teams receive $2.4 million to help breast cancer survivors

A total of $2.4 million has been awarded to five research teams in the Canadian Breast Cancer Research Alliance/Canadian Breast Cancer Foundation Special Research Competition on Psychosocial Aspects of Breast Cancer.

15 Oct 2009

New relocatable radiation therapy system from TomoTherapy

TomoTherapy Incorporated announced today the availability of the industry's first relocatable radiation therapy solution -- TomoMobile™ -- which is designed to quickly and cost-effectively bring cutting-edge radiation therapy solutions to patients in underserved and rural markets.

15 Oct 2009

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

ZIOPHARM Oncology, Inc. announced today positive top line interim data from the multicenter randomized Phase II trial of palifosfamide (ZymafosTM, ZIO-201) treating patients with unresectable or metastatic soft tissue sarcoma. The analysis evaluated 62 patients treated as of the end of September, with 58 being analyzed.

14 Oct 2009

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

Doctors in Latvia have begun treatments using the region's first Novalis Tx(TM) radiosurgery platform from Varian Medical Systems and BrainLAB. Two prostate cancer patients have been treated using Varian's RapidArc® radiotherapy technology at the Riga Eastern Clinical University Hospital.

14 Oct 2009

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

SwitchGear Genomics, Inc., a leading provider of products for studying regulatory elements in the human genome, today announced the availability of the first cost-effective, high-throughput research tools for screening transcriptional activation and repression in a number of key biological pathways.

14 Oct 2009

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Abbott (NYSE: ABT) today announced financial results for the third quarter ended Sept. 30, 2009.

14 Oct 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, has expanded its compassionate use program for PV-10, making the agent, which is being developed as a therapeutic agent for a broad spectrum of cancers, available for select cancer patients in the United States. The program is already in progress in Australia, where it was initiated in June 2009.

14 Oct 2009

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Progenics Pharmaceuticals, Inc. today announced that it has entered into an agreement with Wyeth Pharmaceuticals, a division of Wyeth under which Progenics is regaining all worldwide rights to the RELISTOR® franchise from Wyeth Pharmaceuticals, which Progenics had previously licensed to Wyeth Pharmaceuticals.

14 Oct 2009

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Elsevier Business Intelligence and Windhover Conferences have announced a major addition to the lineup for their upcoming Therapeutic Area Partnerships event, Nov. 17-19 in Boston, MA. In Roche and Genentech: Understanding Their Collaborative Business Development Model, the two executives who designed and implemented the radical new collaborative business model will share exactly how they make this relationship work and the outlook for the business model in the future.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

Institute of Medicine elects researcher from The Children's Hospital of Philadelphia as its member

A prominent scientist at The Children's Hospital of Philadelphia, Thomas Curran, Ph.D., FRS, has been elected to the Institute of Medicine. Dr. Curran has long been a leading researcher in pediatric oncology.

14 Oct 2009

Prime Healthcare Services renews its supply chain relationship with Broadlane

Broadlane, the leading cost-management company for healthcare providers, announced today that Prime Healthcare Services in Victorville, California has renewed its supply chain relationship with Broadlane for another five years.

14 Oct 2009

Decreased expression of tumor suppressor gene PTEN transforms neurofibromas into cancer

Researchers at UCLA's Jonsson Comprehensive Cancer Center showed for the first time that the loss or decreased expression of the tumor suppressor gene PTEN plays a central role in the malignant transformation of benign nerve tumors called neurofibromas into a malignant and extremely deadly form of sarcoma.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

14 Oct 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Dyax Corp. announced today new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis.

13 Oct 2009

Hartford Hospital awards three-year contract to Zix Corporation for email encryption services

Zix Corporation, the leader in email encryption services, today announced that Hartford Hospital, a Connecticut-based hospital, has signed a three-year contract for the company's email encryption services.

13 Oct 2009

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Provectus Pharmaceuticals, Inc., a development stage oncology and dermatology biopharmaceutical company, has completed patient accrual and initial treatment in its Phase 2 trial of PH-10 for the treatment of plaque psoriasis. This milestone marks the third Phase 2 clinical trial for which Provectus has completed patient accrual since May 2009.

13 Oct 2009

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Proteolix, Inc. today announced that it has signed a definitive agreement to be acquired by Onyx Pharmaceuticals, Inc.

13 Oct 2009

Oncology News and Research

Further Reading

Five research teams receive $2.4 million to help breast cancer survivors

New relocatable radiation therapy system from TomoTherapy

Positive data from ZIOPHARM's palifosfamide sarcoma Phase II trial

Riga Eastern Clinical University Hospital commences treatment with the Novalis Tx radiosurgery platform

SwitchGear Genomics introduces high-throughput research tools for profiling biological pathway regulation

Abbott announces financial results for the third quarter ended Sept. 30, 2009

Provectus Pharmaceuticals commences compassionate use program of PV-10 for cancer

Progenics Pharmaceuticals and Wyeth Pharmaceuticals sign license agreement

Roche and Genentech to discuss their radical collaborative business model at the Windhover Conference

Breakthrough in pancreatic cancer treatment

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Institute of Medicine elects researcher from The Children's Hospital of Philadelphia as its member

Prime Healthcare Services renews its supply chain relationship with Broadlane

Decreased expression of tumor suppressor gene PTEN transforms neurofibromas into cancer

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Hartford Hospital awards three-year contract to Zix Corporation for email encryption services

Provectus Pharmaceuticals completes initial treatment in Phase 2 trial of PH-10 for plaque psoriasis

Onyx Pharmaceuticals signs definitive agreement to acquire Proteolix

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News